US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.03 against a street estimate of 0.01 — a beat of 200.0%.
Analysts rate Cronos Group Inc a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $2.46.
| Fund | Stake |
|---|---|
| D. E. Shaw & Co LP | 2.40% |
| Chescapmanager LLC | 2.16% |
| Tidal Investments LLC. | 1.02% |
| Dimensional Fund Advisors, Inc. | 0.83% |
| Arrowstreet Capital Limited Partnership | 0.54% |
| Renaissance Technologies Corp | 0.47% |
| Mackenzie Investments | 0.43% |
| CIBC World Markets Inc. | 0.38% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 CRONOS GROUP INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Cronos Group Inc., British Columbia, Canada; trades as CRON on NASDAQ • Filing Date | 2026-09-11 |
| Quarterly report · Q2 2026 CRONOS GROUP INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Revenue (Q2 2026): $53.0 million (Q2 2025: $33.5 million) – up 58% year-over-year • | 2026-08-06 |
| Results announced · Q3 2026 CRONOS GROUP Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Net revenue Q2 2026: $53.0 million, up 58% year-over-year (51% organic, constant-currency ba | 2026-08-06 |
| Shareholder vote results · Q2 2026 CRONOS GROUP INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held June 18, 2026 • Total votes cast for director elections: | 2026-06-22 |
| Quarterly report · Q1 2026 CRONOS GROUP INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net revenue (after excise taxes): $45.2 million for Q1 2026, up 40% from $32.3 million i | 2026-05-11 |
| Results announced · Q2 2026 CRONOS GROUP Q1 2026 RESULTS SUMMARY HEADLINE NUMBERS • Net revenue increased 40% year-over-year to $45.2 million in Q1 2026 (vs. $32.3 million in Q | 2026-05-11 |
| Proxy statement · Q4 2025 CRONOS GROUP INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Director Election): Elect seven directors by pluralit | 2026-04-24 |
| Annual report FY2025 CRONOS GROUP INC. — 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market Capitalization (as of June 30, 2025): $379.9 million (calculated at $1.91 p | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of CanAdelaar, making it a wholly owned subsidiary Cronos Group completed its acquisition of CanAdelaar B.V. on October 15, 2026, making it a wholly owned subsidiary. CanAdelaar is one of only 10 licensed cannabis growers in the Netherlands’ | 2026-10-15 |
| Amendment extends timeline for CanAdelaar cannabis grower acquisition closing Cronos Group announced three developments on May 11, 2026. First, the company extended the deadline for acquiring CanAdelaar B.V., a licensed Dutch cannabis grower, from June 9 to September | 2026-05-11 |
| Enters material definitive agreement for share purchase transaction Cronos Group Inc., a medicinal chemicals and botanical products company, filed an 8-K announcement on December 9, 2025, disclosing entry into a material definitive agreement. The filing indi | 2025-12-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cronos Group Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.